{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:43:31Z","timestamp":1767872611485,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"DOI":"10.7759\/cureus.101063","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:47:07Z","timestamp":1767862027000},"source":"Crossref","is-referenced-by-count":0,"title":["Retrospective Analysis of Oral Tofacitinib Treatment for Alopecia Areata at a Tertiary Care Hospital in Saudi Arabia"],"prefix":"10.7759","author":[{"given":"Faisal A","family":"Aleidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monirah O","family":"Almadhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyad H","family":"Altassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lama F","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijad","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haneen M","family":"Almansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad  R","family":"Alhowil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadeem A","family":"Alsultani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad","family":"Fahad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fay","family":"Thawab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10347","article-title":"Prevalence of alopecia areata in Saudi Arabia: cross-sectional descriptive study","volume":"12","author":"Al-Ajlan A","year":"2020","unstructured":"Al-Ajlan A, Alqahtani ME, Alsuwaidan S, Alsalhi A. Prevalence of alopecia areata in Saudi Arabia: cross-sectional descriptive study. Cureus. 2020, 12:e10347. 10.7759\/cureus.10347","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00991-3","article-title":"Diagnosis and management of alopecia areata: a Saudi Expert Consensus Statement (2023)","volume":"13","author":"Fatani MI","year":"2023","unstructured":"Fatani MI, Alkhalifah A, Alruwaili AF, et al.. Diagnosis and management of alopecia areata: a Saudi Expert Consensus Statement (2023). Dermatol Ther (Heidelb). 2023, 13:2129-51. 10.1007\/s13555-023-00991-3","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt CH","year":"2017","unstructured":"Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017, 3:17011. 10.1038\/nrdp.2017.11","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1577115","article-title":"Janus kinase inhibitors for alopecia areata: a review of clinical data","volume":"16","author":"Sun Y","year":"2025","unstructured":"Sun Y, Li Q, Zhang Y, Liu Y. Janus kinase inhibitors for alopecia areata: a review of clinical data. Front Immunol. 2025, 16:1577115. 10.3389\/fimmu.2025.1577115","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0001","article-title":"Treatment of alopecia areata with tofacitinib","volume":"153","author":"Ibrahim O","year":"2017","unstructured":"Ibrahim O, Bayart CB, Hogan S, Piliang M, Bergfeld WF. Treatment of alopecia areata with tofacitinib. JAMA Dermatol. 2017, 153:600-2. 10.1001\/jamadermatol.2017.0001","journal-title":"JAMA Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan K","year":"2019","unstructured":"Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019, 33:850-6. 10.1111\/jdv.15489","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.12425","article-title":"Effectiveness and predictive factors of response to tofacitinib therapy in 125 patients with alopecia areata: a single-centre real-world retrospective study","volume":"103","author":"Huang J","year":"2023","unstructured":"Huang J, Qian P, Tang Y, Li J, Liu F, Shi W. Effectiveness and predictive factors of response to tofacitinib therapy in 125 patients with alopecia areata: a single-centre real-world retrospective study. Acta Derm Venereol. 2023, 103:adv12425. 10.2340\/actadv.v103.12425","journal-title":"Acta Derm Venereol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2022.05.002","article-title":"A retrospective study of oral tofacitinib therapy for alopecia areata","volume":"98","author":"Lima XT","year":"2023","unstructured":"Lima XT, Bambery M, Alora MB. A retrospective study of oral tofacitinib therapy for alopecia areata. An Bras Dermatol. 2023, 98:221-4. 10.1016\/j.abd.2022.05.002","journal-title":"An Bras Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15871","article-title":"Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: a prospective, open-label, single-center study in Asian Arab population","volume":"35","author":"Husein-ElAhmed H","year":"2022","unstructured":"Husein-ElAhmed H, Abdulla N, Al-Obaidli A, Ali-Alam M, Steinhoff M. Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: a prospective, open-label, single-center study in Asian Arab population. Dermatol Ther. 2022, 35:e15871. 10.1111\/dth.15871","journal-title":"Dermatol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.13475","article-title":"Drug survival and long-term outcome of tofacitinib in patients with alopecia areata: a retrospective study","volume":"103","author":"Huang J","year":"2023","unstructured":"Huang J, Deng S, Li J, et al.. Drug survival and long-term outcome of tofacitinib in patients with alopecia areata: a retrospective study. Acta Derm Venereol. 2023, 103:adv13475. 10.2340\/actadv.v103.13475","journal-title":"Acta Derm Venereol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/abmj.abmj_21_23","article-title":"Systemic tofacitinib in alopecia areata: a single center retrospective descriptive cohort study","volume":"25","author":"Al Ali A","year":"2024","unstructured":"Al Ali A, Al Ali Y, Al Maashari RS. Systemic tofacitinib in alopecia areata: a single center retrospective descriptive cohort study. Arab Board Med J. 2024, 25:25-30. 10.4103\/abmj.abmj_21_23","journal-title":"Arab Board Med J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(99)70195-7","article-title":"Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation","volume":"40","author":"Olsen E","year":"1999","unstructured":"Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, Stenn K. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol. 1999, 40:242-6. 10.1016\/s0190-9622(99)70195-7","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.041","article-title":"Tofacitinib therapy for children with severe alopecia areata","volume":"80","author":"Dai YX","year":"2019","unstructured":"Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata. J Am Acad Dermatol. 2019, 80:1164-6. 10.1016\/j.jaad.2018.12.041","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.24875\/BMHIM.19000005","article-title":"Tofacitinib as a treatment of alopecia areata in adolescents","volume":"76","author":"Morales-Miranda AY","year":"2019","unstructured":"Morales-Miranda AY, Bueno-Arias GM, Aguirre-F\u00e9lix \u00d3G, Tovar-Franco R. Tofacitinib as a treatment of alopecia areata in adolescents. Bol Med Hosp Infant Mex. 2019, 76:182-7. 10.24875\/BMHIM.19000005","journal-title":"Bol Med Hosp Infant Mex"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari A","year":"2018","unstructured":"Jabbari A, Sansaricq F, Cerise J, et al.. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol. 2018, 138:1539-45. 10.1016\/j.jid.2018.01.032","journal-title":"J Invest Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin M","year":"2016","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG, et al.. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016, 1:e89776. 10.1172\/jci.insight.89776","journal-title":"JCI Insight"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.041","article-title":"Tofacitinib for the treatment of alopecia areata in preadolescent children","volume":"80","author":"Craiglow BG","year":"2019","unstructured":"Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. J Am Acad Dermatol. 2019, 80:568-70. 10.1016\/j.jaad.2018.08.041","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13553","article-title":"Tofacitinib treatment in a severe pediatric alopecia areata: a case report and a literature review","volume":"30","author":"Ma Y","year":"2024","unstructured":"Ma Y, Wang W, Shi D. Tofacitinib treatment in a severe pediatric alopecia areata: a case report and a literature review. Skin Res Technol. 2024, 30:e13553. 10.1111\/srt.13553","journal-title":"Skin Res Technol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.08.024","article-title":"Clinical response to oral tofacitinib in pediatric patients with alopecia areata","volume":"31","author":"Youssef S","year":"2023","unstructured":"Youssef S, Bordone LA. Clinical response to oral tofacitinib in pediatric patients with alopecia areata. JAAD Case Rep. 2023, 31:83-8. 10.1016\/j.jdcr.2022.08.024","journal-title":"JAAD Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203684","article-title":"The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis","volume":"73","author":"Pope JE","year":"2014","unstructured":"Pope JE, Haraoui B, Thorne JC, Vieira A, Poulin-Costello M, Keystone EC. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis. 2014, 73:2144-51. 10.1136\/annrheumdis-2013-203684","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-025-04035-y","article-title":"Switching JAK inhibitors: evaluating baricitinib's effectiveness in alopecia areata after tofacitinib failure","volume":"317","author":"Ehsani A","year":"2025","unstructured":"Ehsani A, Razavi Z, Rahimnia A, Ehsani A, Saberi F, Aryanian Z, Babaie H. Switching JAK inhibitors: evaluating baricitinib's effectiveness in alopecia areata after tofacitinib failure. Arch Dermatol Res. 2025, 317:491. 10.1007\/s00403-025-04035-y","journal-title":"Arch Dermatol Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00997-x","article-title":"Hair loss profiles and Ritlecitinib efficacy in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b\/3 study","volume":"13","author":"Tha\u00e7i D","year":"2023","unstructured":"Tha\u00e7i D, Tziotzios C, Ito T, et al.. Hair loss profiles and Ritlecitinib efficacy in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b\/3 study. Dermatol Ther (Heidelb). 2023, 13:2621-34. 10.1007\/s13555-023-00997-x","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452381-retrospective-analysis-of-oral-tofacitinib-treatment-for-alopecia-areata-at-a-tertiary-care-hospital-in-saudi-arabia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:47:08Z","timestamp":1767862028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452381-retrospective-analysis-of-oral-tofacitinib-treatment-for-alopecia-areata-at-a-tertiary-care-hospital-in-saudi-arabia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.101063","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}